Michael LISANTI, MD, PhD

University of Salford, MANCHESTER, UK

Michael Lisanti began his education at New York University (1981-1985), graduating Magna Cum Laude in Chemistry. He obtained his MD-PhD degrees at Cornell University Medical College in Cell Biology and Genetics (Cornell University Tri-Institutional MD-PhD Program (Cornell University, together with Rockefeller University and Memorial Sloan-Kettering), New York, USA; 1985-1992).
From 1992-1996, he was a Fellow at the Whitehead Institute at MIT (Affiliated with Dr. Harvey Lodish's Laboratory). After several distinguished appointments at the Albert Einstein College of Medicine and the Kimmel Center, he joined the Breakthrough Breast Cancer Research Unit in 2012 as Professor of Cancer Biology, at The University of Manchester, in the United Kingdom (UK). Following his appointment to the Kimmel Cancer Center in 2006, he was selected for the leadership of the Program in Molecular Biology and Genetics of Cancer.
In 2009, he became the Chair of the Department of Stem Cell Biology and Regenerative Medicine at Thomas Jefferson University. He also served as the former Editor-in-Chief of the American Journal of Pathology.
In Manchester, I previously held the Muriel Edith Rickman Chair of Breast Oncology. Previously, he has lectured in various M.D. and Ph.D level graduate courses in Biochemistry, Cell Biology, Pharmacology, Pathology and Clinical Medicine, among others. His research programme focuses on the role of Caveolin-1 (Cav-1) in the pathogenesis of human breast cancer, with a strong emphasis on its role in signalling, cancer, metabolism and stem cell biology. In 1993-94, his laboratory was among the first to propose that signal transduction takes place in an organized fashion, within lipid rafts and caveolae. This signalling model was heretical in the early 1990s, and is now well accepted today.
His laboratory was also the first to propose, in 2009, the “Reverse Warburg Effect”. This new model for cancer metabolism will facilitate the development of novel diagnostics and therapeutics, driving personalised cancer therapy. Also in 2009, his laboratory discovered a new prognostic biomarker, which has now been validated in >10 different countries word-wide for breast cancer. Its prognostic value has also been extended to DCIS lesions (early breast cancers), prostate cancers, and metastatic melanoma, and it may well represent a universal or widely-applicable cancer biomarker for stratified medicine. He is a member of the American Society for Investigative Pathology (ASIP) and of the American Association for Cancer Research (AACR).